ModAstera is a no-code AI development platform designed for medical applications. It automates predictive modeling for patient risk and outcomes, featuring AI-assisted data annotation and one-click deployment to significantly reduce development time and costs for health tech innovators.
Tempus is a leading technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It leverages one of the world's largest libraries of multimodal clinical and molecular data to help physicians deliver personalized patient care and accelerate the discovery and development of new therapeutics.
ModAstera is a no-code AI development platform designed for medical applications. It automates predictive modeling for patient risk and outcomes, featuring AI-assisted data annotation and one-click deployment to significantly reduce development time and costs for health tech innovators.
Tempus is a leading technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It leverages one of the world's largest libraries of multimodal clinical and molecular data to help physicians deliver personalized patient care and accelerate the discovery and development of new therapeutics.
| Feature | ModAstera | Tempus |
|---|---|---|
| Primary category | Machine Learning | Clinical Support |
| Added | 2025-10-22 | 2025-09-19 |
| Pricing | Freemium | Not verified |
| Official website | www.modastera.com | tempus.com |
| Product type | Website | Website |
| Performance data | ||
| User rating | Not verified | Not verified |
| Comments | 0 | 0 |
| Monthly visits | 250 | 151.5K |
| Monthly growth | -68.4% | 15.9% |
| Favorites | 85 | 121 |
| Details | View details | View details |
Compare ModAstera and Tempus by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
In the ModAstera vs Tempus monthly traffic comparison, ModAstera currently shows 250 visits and Tempus shows 151.5K; Tempus has about 605.8 times the visible traffic of ModAstera, an absolute difference of about 151.2K visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 86.21% | 130.6K |
| 🇮🇳India | 4.87% | 7.4K |
| 🇰🇷Korea, Republic of | 4.08% | 6.2K |
| 🇨🇦Canada | 2.71% | 4.1K |
| 🇳🇬Nigeria | 2.13% | 3.2K |
| Source type | Percentage | Traffic |
|---|---|---|
| Referral | 48.63% | 73.7K |
| Direct | 47.07% | 71.3K |
| 4.3% | 6.5K |
This in-depth ModAstera vs Tempus comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. ModAstera is primarily listed under “Machine Learning”, while Tempus is primarily listed under “Clinical Support”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Primary category (ModAstera: Machine Learning; Tempus: Clinical Support); Pricing (ModAstera: Freemium; Tempus: Not disclosed); Monthly visits (ModAstera: 250; Tempus: 151.5K); Monthly growth (ModAstera: -68.4%; Tempus: 15.9%); Favorites (ModAstera: 85; Tempus: 121). These facts are more useful for selection than brand visibility alone.
In the ModAstera vs Tempus monthly traffic comparison, ModAstera currently shows 250 visits and Tempus shows 151.5K; Tempus has about 605.8 times the visible traffic of ModAstera, an absolute difference of about 151.2K visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
If public market visibility is an important first-pass criterion, investigate Tempus first. The final choice should still follow taxonomy, use case, and a real trial because higher traffic does not prove broader capabilities or better workflow fit.
ModAstera and Tempus currently overlap in shared roles: Bioinformatician, Data Scientist, and Medical Researcher. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
ModAstera's unique categories/tags are Machine Learning, No Code Platform, Medical Ai, AI development, clinical research, data annotation, healthcare AI, and healthtech; Tempus's are Clinical Support, Medical Research, Precision Medicine, AI in healthcare, clinical assistant, clinical trials, drug discovery, and EHR integration. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
ModAstera has no verified rating, 0 comments, 85 favorites, and 88 likes；Tempus has no verified rating, 0 comments, 121 favorites, and 118 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Put ModAstera on the priority trial list when the task aligns with “Machine Learning” and especially Machine Learning, No Code Platform, Medical Ai, AI development, clinical research, and data annotation, or the users include Clinician, Healthcare IT Manager, Health Tech Entrepreneur, and Machine Learning Engineer. This follows recorded positioning and does not imply unlisted capabilities are absent.
ModAstera also currently records: pricing is freemium, product type is website, 250 verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
Put Tempus on the priority trial list when the task aligns with “Clinical Support” and especially Clinical Support, Medical Research, Precision Medicine, AI in healthcare, clinical assistant, and clinical trials, or the users include Clinical Trial Manager, Healthcare Administrator, Oncologist, and Pharmaceutical Scientist. This follows recorded positioning and does not imply unlisted capabilities are absent.
Tempus also currently records: pricing is not verified, product type is website, 151.5K verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in ModAstera and Tempus, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.
